Eikan Mishima1, Emiko Sato2,3, Junya Ito4, Ken-Ichi Yamada5, Chitose Suzuki2, Yoshitsugu Oikawa6, Tetsuro Matsuhashi6, Koichi Kikuchi2, Takafumi Toyohara2, Takehiro Suzuki2, Sadayoshi Ito2,7, Kiyotaka Nakagawa4, Takaaki Abe2,8,9. 1. Divisions of Nephrology, Endocrinology, and Vascular Medicine and eikan@med.tohoku.ac.jp. 2. Divisions of Nephrology, Endocrinology, and Vascular Medicine and. 3. Department of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan. 4. Food and Biodynamic Chemistry Laboratory, Graduate School of Agricultural Science, Tohoku University, Sendai, Japan. 5. Physical Chemistry for Life Science Laboratory, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan. 6. Pediatrics, and. 7. Katta Public General Hospital, Shiroishi, Japan; and. 8. Department of Medical Science, Tohoku University Graduate School of Biomedical Engineering, Sendai, Japan. 9. Department of Clinical Biology and Hormonal Regulation, Tohoku University Graduate School of Medicine, Sendai, Japan.
Abstract
BACKGROUND: Ferroptosis, nonapoptotic cell death mediated by free radical reactions and driven by the oxidative degradation of lipids, is a therapeutic target because of its role in organ damage, including AKI. Ferroptosis-causing radicals that are targeted by ferroptosis suppressors have not been unequivocally identified. Because certain cytochrome P450 substrate drugs can prevent lipid peroxidation via obscure mechanisms, we evaluated their antiferroptotic potential and used them to identify ferroptosis-causing radicals. METHODS: Using a cell-based assay, we screened cytochrome P450 substrate compounds to identify drugs with antiferroptotic activity and investigated the underlying mechanism. To evaluate radical-scavenging activity, we used electron paramagnetic resonance-spin trapping methods and a fluorescence probe for lipid radicals, NBD-Pen, that we had developed. We then assessed the therapeutic potency of these drugs in mouse models of cisplatin-induced AKI and LPS/galactosamine-induced liver injury. RESULTS: We identified various US Food and Drug Administration-approved drugs and hormones that have antiferroptotic properties, including rifampicin, promethazine, omeprazole, indole-3-carbinol, carvedilol, propranolol, estradiol, and thyroid hormones. The antiferroptotic drug effects were closely associated with the scavenging of lipid peroxyl radicals but not significantly related to interactions with other radicals. The elevated lipid peroxyl radical levels were associated with ferroptosis onset, and known ferroptosis suppressors, such as ferrostatin-1, also functioned as lipid peroxyl radical scavengers. The drugs exerted antiferroptotic activities in various cell types, including tubules, podocytes, and renal fibroblasts. Moreover, in mice, the drugs ameliorated AKI and liver injury, with suppression of tissue lipid peroxidation and decreased cell death. CONCLUSIONS: Although elevated lipid peroxyl radical levels can trigger ferroptosis onset, some drugs that scavenge lipid peroxyl radicals can help control ferroptosis-related disorders, including AKI.
BACKGROUND: Ferroptosis, nonapoptotic cell death mediated by free radical reactions and driven by the oxidative degradation of lipids, is a therapeutic target because of its role in organ damage, including AKI. Ferroptosis-causing radicals that are targeted by ferroptosis suppressors have not been unequivocally identified. Because certain cytochrome P450 substrate drugs can prevent lipid peroxidation via obscure mechanisms, we evaluated their antiferroptotic potential and used them to identify ferroptosis-causing radicals. METHODS: Using a cell-based assay, we screened cytochrome P450 substrate compounds to identify drugs with antiferroptotic activity and investigated the underlying mechanism. To evaluate radical-scavenging activity, we used electron paramagnetic resonance-spin trapping methods and a fluorescence probe for lipid radicals, NBD-Pen, that we had developed. We then assessed the therapeutic potency of these drugs in mouse models of cisplatin-induced AKI and LPS/galactosamine-induced liver injury. RESULTS: We identified various US Food and Drug Administration-approved drugs and hormones that have antiferroptotic properties, including rifampicin, promethazine, omeprazole, indole-3-carbinol, carvedilol, propranolol, estradiol, and thyroid hormones. The antiferroptotic drug effects were closely associated with the scavenging of lipid peroxyl radicals but not significantly related to interactions with other radicals. The elevated lipid peroxyl radical levels were associated with ferroptosis onset, and known ferroptosis suppressors, such as ferrostatin-1, also functioned as lipid peroxyl radical scavengers. The drugs exerted antiferroptotic activities in various cell types, including tubules, podocytes, and renal fibroblasts. Moreover, in mice, the drugs ameliorated AKI and liver injury, with suppression of tissue lipid peroxidation and decreased cell death. CONCLUSIONS: Although elevated lipid peroxyl radical levels can trigger ferroptosis onset, some drugs that scavenge lipid peroxyl radicals can help control ferroptosis-related disorders, including AKI.
Authors: Mi Ra Noh; Ki Young Kim; Sang Jun Han; Jee In Kim; Hwa-Young Kim; Kwon Moo Park Journal: Antioxid Redox Signal Date: 2017-03-20 Impact factor: 8.401
Authors: Omkar Zilka; Ron Shah; Bo Li; José Pedro Friedmann Angeli; Markus Griesser; Marcus Conrad; Derek A Pratt Journal: ACS Cent Sci Date: 2017-03-07 Impact factor: 14.553
Authors: Filipa Lopes-Coelho; Filipa Martins; Ana Hipólito; Cindy Mendes; Catarina O Sequeira; Rita F Pires; António M Almeida; Vasco D B Bonifácio; Sofia A Pereira; Jacinta Serpa Journal: Front Oncol Date: 2021-05-10 Impact factor: 6.244
Authors: Megan Conlon; Carson D Poltorack; Giovanni C Forcina; David A Armenta; Melodie Mallais; Marcos A Perez; Alex Wells; Alexis Kahanu; Leslie Magtanong; Jennifer L Watts; Derek A Pratt; Scott J Dixon Journal: Nat Chem Biol Date: 2021-03-08 Impact factor: 15.040